SEARCH

SEARCH BY CITATION

References

  • Adams J. R., Van Netten H., Schulzer M., Mak E., McKenzie J., Strongosky A., Sossi V., Ruth T. J., Lee C. S., Farrer M., Gasser T., Uitti R. J., Calne D. B., Wszolek Z. K. and Stoessl A. J. (2005) PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation. Brain 128, 27772785.
  • Bader V., Ran Z. X., Lubbert H. and Stichel C. C. (2005) Expression of DJ-1 in the adult mouse CNS. Brain Res. 1041, 102111.
  • Baekelandt V., Eggermont K., Michiels M., Nuttin B. and Debyser Z. (2003) Optimized lentiviral vector production and purification procedure prevents immune response after transduction of mouse brain. Gene Ther. 23, 19331940.
  • Bosgraaf L. and Van Haastert P. J. (2003) Roc, a Ras/GTPase domain in complex proteins. Biochim. Biophys. Acta 1643, 510.
  • Bradford M. M. (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 72, 248254.
  • D'Agata V., Zhao W. and Cavallaro S. (2000) Cloning and distribution of the rat parkin mRNA. Brain Res. Mol Brain Res. 75, 345349.
  • Galter D., Westerlund M., Carmine A., Lindqvist E., Sydow O. and Olson L. (2006) LRRK2 expression linked to dopamine-innervated areas. Ann. Neurol. 59, 714719.
  • Gasser T. (2005) Genetics of Parkinson's disease. Curr. Opin. Neurol. 18, 363369.
  • Gerfen C. R. (2004) Basal Ganglia. In: The Rat Nervous System (Paxinos, G., ed.), pp. 455507. Elsevier, San Diego, USA.
  • Giasson B. I., Covy J. P., Bonini N. M., Hurtig H. I., Farrer M. J., Trojanowski J. Q. and Van Deerlin V. M. (2006) Biochemical and pathological characterization of Lrrk2. Ann. Neurol. 59, 315322.
  • Gloeckner C. J., Kinkl N., Schumacher A., Braun R. J., O'neill E., Meitinger T., Kolch W., Prokisch H. and Ueffing M. (2005) The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity. Hum Mol Genet 15, 223232.
  • Hatano Y., Li Y., Sato K., Asakawa S., Yamamura Y., Tomiyama H., Yoshino H., Asahina M., Kobayashi S., Hassin-Baer S., Lu C. S., Ng A. R., Rosales R. L., Shimizu N., Toda T., Mizuno Y. and Hattori N. (2004) Novel PINK1 mutations in early-onset parkinsonism. Ann. Neurol. 56, 424427.
  • Healy D. G., Abou-Sleiman P. M., Gibson J. M., Ross O. A., Jain S., Gandhi S., Gosal D., Muqit M. M., Wood N. W. and Lynch T. (2004) PINK1 (PARK6) associated Parkinson disease in Ireland. Neurology 63, 14861488.
  • Hernandez D. G., Paisan-Ruiz C., McInerney-Leo A., Jain S., Meyer-Lindenberg A., Evans E. W., Berman K. F., Johnson J., Auburger G., Schaffer A. A., Lopez G. J., Nussbaum R. L. and Singleton A. B. (2005) Clinical and positron emission tomography of Parkinson's disease caused by LRRK2. Ann. Neurol. 57, 453456.
  • Hong L., Ko H. W., Gwag B. J., Joe E., Lee S., Kim Y. T. and Suh Y. H. (1998) The cDNA cloning and ontogeny of mouse alpha-synuclein. Neuroreport 9, 12391243.
  • Khan N. L., Valente E. M., Bentivoglio A. R., Wood N. W., Albanese A., Brooks D. J. and Piccini P. (2002) Clinical and subclinical dopaminergic dysfunction in PARK6-linked parkinsonism: an 18F-dopa PET study. Ann. Neurol. 52, 849853.
  • Kish S. J., Shannak K. and HornykiewicZ. O. (1988) Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N Engl. J. Med. 318, 876880.
  • Mata I. F., Kachergus J. M., Taylor J. P., Lincoln S., Aasly J., Lynch T., Hulihan M. M., Cobb S. A., Wu R. M., Lu C. S., LahoZ. C., Wszolek Z. K. and Farrer M. J. (2005) Lrrk2 pathogenic substitutions in Parkinson's disease. Neurogenetics 6, 171177.
  • Melrose H., Lincoln S., Tyndall G., Dickson D. and Farrer M. (2006) Anatomical localization of leucine-rich repeat kinase 2 in mouse brain. Neuroscience 139, 791794.
  • Nakajima A., Kataoka K., Hong M., Sakaguchi M. and Huh N. H. (2003) BRPK, a novel protein kinase showing increased expression in mouse cancer cell lines with higher metastatic potential. Cancer Lett. 201, 195201.
  • Paisan-Ruiz C., Jain S., Evans E. W., Gilks W. P., Van Der Simon J. B. M., De Munain A. L., Aparicio S., Gil A. M., Khan N., Johnson J., Martinez J. R., Nicholl D., Carrera I. M., Pena A. S., De Silva R., Lees A., Marti-Masso J. F., Perez-Tur J., Wood N. W. and Singleton A. B. (2004) Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 44, 595600.
  • Rogaeva E., Johnson J., Lang A. E., Gulick C., Gwinn-Hardy K., Kawarai T., Sato C., Morgan A., Werner J., Nussbaum R., Petit A., Okun M. S., McInerney A., Mandel R., Groen J. L., Fernandez H. H., Postuma R., Foote K. D., Salehi-Rad S., Liang Y., Reimsnider S., Tandon A., Hardy J., George-Hyslop P. and Singleton A. B. (2004) Analysis of the PINK1 gene in a large cohort of cases with Parkinson disease. Arch. Neurol. 61, 18981904.
  • Rohe C. F., Montagna P., Breedveld G., Cortelli P., Oostra B. A. and Bonifati V. (2004) Homozygous PINK1 C-terminus mutation causing early-onset parkinsonism. Ann. Neurol. 56, 427431.
  • Ross O. A., Toft M., Whittle A. J., Johnson J. L., Papapetropoulos S., Mash D. C., Litvan I., Gordon M. F., Wszolek Z. K., Farrer M. J. and Dickson D. W. (2006) Lrrk2 and Lewy body disease. Ann. Neurol. 59, 388393.
  • Shang H., Lang D., Jean-Marc B. and Kaelin-Lang A. (2004) Localization of DJ-1 mRNA in the mouse brain. Neurosci. Lett. 367, 273277.
  • Simon-SancheZ. J., Herranz-Perez V., Olucha-Bordonau F. and Perez-Tur J. (2006) LRRK2 is expressed in areas affected by Parkinson's disease in the adult mouse brain. Eur J. Neurosci. 23, 659666.
  • Smith W. W., Pei Z., Jiang H., Moore D. J., Liang Y., West A. B., Dawson V. L., Dawson T. M. and Ross C. A. (2005) Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration. Proc. Natl Acad. Sci. USA 102, 18 67618 681.
  • Stichel C. C., Augustin M., Kuhn K., Zhu X. R., Engels P., Ullmer C. and Lubbert H. (2000) Parkin expression in the adult mouse brain. Eur J. Neurosci. 12, 41814194.
  • Taymans J.-M., Kia H. K., Claes R., Cruz C., Leysen J. E. and Langlois X. (2004) Dopamine receptor mediated regulation of RGS2 and RGS4 mRNA differentially depends on ascending dopamine projections and time. European J. Neuroscience 19, 22492260.
  • Tecott L. H., Eberwine J. H., Barchas J. D. and Valentino K. L. (1987) Methodological Considerations in the Utilization of In Situ Hybridization. In: Situ Hybridization: Applications to Neurobiology (Valentino, K. L., Eberwine, J. H. and Barchas, J. D., eds), pp. 324. Oxford University Press, New York.
  • Unoki M. and Nakamura Y. (2001) Growth-suppressive effects of BPOZ. and EGR2, two genes involved in the PTEN signaling pathway. Oncogene 20, 44574465.
  • Valente E. M., Abou-Sleiman P. M., Caputo V., Muqit M. M., Harvey K., Gispert S., Ali Z., Del Turco D., Bentivoglio A. R., Healy D. G., Albanese A., Nussbaum R., Gonzalez-Maldonado R., Deller T., Salvi S., Cortelli P., Gilks W. P., Latchman D. S., Harvey R. J., Dallapiccola B., Auburger G. and Wood N. W. (2004) Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 304, 11581160.
  • West A. B., Moore D. J., Biskup S., Bugayenko A., Smith W. W., Ross C. A., Dawson V. L. and Dawson T. M. (2005) Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc. Natl Acad. Sci. U S A 102, 16 84216 847.
  • Zimprich A., Biskup S., Leitner P., Lichtner P., Farrer M., Lincoln S., Kachergus J., Hulihan M., Uitti R. J., Calne D. B., Stoessl A. J., Pfeiffer R. F., Patenge N., Carbajal I. C., Vieregge P., Asmus F., Muller-Myhsok B., Dickson D. W., Meitinger T., Strom T. M., Wszolek Z. K. and Gasser T. (2004) Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44, 601607.